Payment overview · 2025
General Payments
$62.03
3 reported records · 3 companies
Healthcare provider profile · identity verified
Muhammad Tahir, MD
Allopathic & Osteopathic Physicians|Family Medicine · BROOKLYN, NY · NPI 1275611790
Verified facts
What the public records show
CMS Open Payments records show Muhammad Tahir, MD received $62.03 in general payments during 2025 across 3 reported records.
Boehringer Ingelheim Pharmaceuticals, Inc. accounted for 44.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Jardiance by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $27.65 | 44.6% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $20.35 | 32.8% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.03 | 22.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $62.03 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JASCAYD Normalized: jascayd |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $27.65 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $20.35 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $14.03 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $14.03 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 405 | 85 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 305 | 64 |
| Amlodipine Besylate | Amlodipine Besylate | 267 | 51 |
| Losartan Potassium | Losartan Potassium | 260 | 43 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 245 | 45 |
| Metformin Hcl | Metformin Hcl | 210 | 35 |
| Metoprolol Succinate | Metoprolol Succinate | 204 | 34 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 191 | 32 |
| Omeprazole | Omeprazole | 170 | 34 |
| Pantoprazole Sodium | Pantoprazole Sodium | 141 | 29 |
| Januvia | Sitagliptin Phosphate | 140 | 23 |
| Zolpidem Tartrate | Zolpidem Tartrate | 132 | 32 |
| Nifedipine Er | Nifedipine | 129 | 23 |
| Levothyroxine Sodium | Levothyroxine Sodium | 123 | 22 |
| Simvastatin | Simvastatin | 122 | 21 |
| Folic Acid | Folic Acid | 118 | 16 |
| Tamsulosin Hcl | Tamsulosin Hcl | 114 | 22 |
| Famotidine | Famotidine | 110 | 24 |
| Gabapentin | Gabapentin | 95 | 25 |
| Ibuprofen | Ibuprofen | 95 | 25 |
| Diclofenac Sodium | Diclofenac Sodium | 92 | 36 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 87 | 14 |
| Meclizine Hcl | Meclizine Hcl | 86 | 22 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 84 | 11 |
| Amoxicillin | Amoxicillin | 77 | 46 |
| Hydrochlorothiazide | Hydrochlorothiazide | 77 | 12 |
| Meloxicam | Meloxicam | 72 | 19 |
| Trulicity | Dulaglutide | 68 | 13 |
| Ventolin Hfa | Albuterol Sulfate | 65 | 22 |
| Azithromycin | Azithromycin | 64 | 42 |
| Clopidogrel | Clopidogrel Bisulfate | 56 | suppressed |
| Furosemide | Furosemide | 54 | 17 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 53 | 16 |
| Symbicort | Budesonide/Formoterol Fumarate | 53 | 13 |
| Linzess | Linaclotide | 52 | 14 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 50 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 50 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 49 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 49 | suppressed |
| Prednisone | Prednisone | 45 | 25 |
| Fluticasone Propionate | Fluticasone Propionate | 41 | 17 |
| Glipizide | Glipizide | 41 | suppressed |
| Levetiracetam | Levetiracetam | 40 | suppressed |
| Carvedilol | Carvedilol | 39 | suppressed |
| Novolog Flexpen | Insulin Aspart | 38 | suppressed |
| Lisinopril | Lisinopril | 37 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 36 | 11 |
| Eliquis | Apixaban | 35 | suppressed |
| Finasteride | Finasteride | 35 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 34 | 11 |
| Donepezil Hcl | Donepezil Hcl | 34 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 34 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 34 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 32 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 32 | suppressed |
| Atenolol | Atenolol | 31 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 31 | suppressed |
| Spironolactone | Spironolactone | 31 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 30 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 30 | suppressed |
| Allopurinol | Allopurinol | 29 | suppressed |
| Alprazolam | Alprazolam | 29 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 29 | suppressed |
| Ozempic | Semaglutide | 27 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 26 | suppressed |
| Jardiance | Empagliflozin | 26 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 26 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 25 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 25 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Lidocaine | Lidocaine | 25 | 11 |
| Vascepa | Icosapent Ethyl | 22 | suppressed |
| Dutasteride | Dutasteride | 21 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 21 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 19 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 18 | suppressed |
| Glipizide Er | Glipizide | 18 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 18 | 15 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Lidocaine Hcl Viscous | Lidocaine Hcl | 17 | 15 |
| Mounjaro | Tirzepatide | 17 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 16 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 15 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 15 | 11 |
| Doxazosin Mesylate | Doxazosin Mesylate | 15 | suppressed |
| Fluocinonide | Fluocinonide | 15 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 15 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 14 | suppressed |
| Entresto | Sacubitril/Valsartan | 14 | suppressed |
| Fenofibrate | Fenofibrate | 14 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 13 | suppressed |
| Mirtazapine | Mirtazapine | 13 | suppressed |
| Valsartan | Valsartan | 13 | suppressed |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 12 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 12 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 12 | suppressed |
| Clonazepam | Clonazepam | 12 | suppressed |
| Ezetimibe | Ezetimibe | 12 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 12 | suppressed |
| Lacosamide | Lacosamide | 12 | suppressed |
| Loperamide | Loperamide Hcl | 12 | suppressed |
| Naproxen | Naproxen | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Ranolazine Er | Ranolazine | 12 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 12 | suppressed |
| Sucralfate | Sucralfate | 12 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 12 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Cephalexin | Cephalexin | 11 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Haloperidol | Haloperidol | 11 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 11 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 11 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 11 | suppressed |
| Sulfasalazine | Sulfasalazine | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $62.03 · 3 records | Boehringer Ingelheim Pharmaceuticals, Inc. | ACCRUFER, JASCAYD, OTEZLA, REPATHA | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error